4-((2,4-dioxo-6-(piperazin-1-yl)-3,4-dihydropyrimidin-1(2H)-yl)methyl)phenyl isoquinoline-5-sulfonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-((2,4-dioxo-6-(piperazin-1-yl)-3,4-dihydropyrimidin-1(2H)-yl)methyl)phenyl isoquinoline-5-sulfonate
• 英文别名: [4-[(2,4-Dioxo-6-piperazin-1-ylpyrimidin-1-yl)methyl]phenyl] isoquinoline-5-sulfonate；[4-[(2,4-dioxo-6-piperazin-1-ylpyrimidin-1-yl)methyl]phenyl] isoquinoline-5-sulfonate
• 化学式: C₂₄H₂₃N₅O₅S
• 分子量: 493.543
• InChiKey: ZRIKXSZEDXMEIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-((2,4-dioxo-6-(piperazin-1-yl)-3,4-dihydropyrimidin-1(2H)-yl)methyl)phenyl isoquinoline-5-sulfonate 、 三甲基乙酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以93.5%的产率得到4-((2,4-dioxo-6-(4-pivaloylpiperazin-1-yl)-3,4-dihydropyrimidin-1(2H)-yl)methyl)phenyl isoquinoline-5-sulfonate
  参考文献：
  名称：

  신규한 우라실 유도체 및 이의 용도

  摘要：

  This invention relates to various novel uracil derivatives and compositions for inhibiting P2X receptor activity, which include them as active ingredients. The invention can be useful for the prevention or treatment of various diseases associated with the activity of P2X receptors, such as chronic inflammatory diseases, inflammatory pain, neuropathic pain, autoimmune diseases, or degenerative diseases.

  公开号：

  KR101732732B1
• 作为产物：
  描述：

  (4-(bromomethyl)phenoxy)(tert-butyl)dimethylsilane 在 哌啶 、 sodium hydride 、 碳酸氢钠 、 三乙胺 、 乙酰氯 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.75h， 生成 4-((2,4-dioxo-6-(piperazin-1-yl)-3,4-dihydropyrimidin-1(2H)-yl)methyl)phenyl isoquinoline-5-sulfonate
  参考文献：
  名称：

  신규한 우라실 유도체 및 이의 용도

  摘要：

  This invention relates to various novel uracil derivatives and compositions for inhibiting P2X receptor activity, which include them as active ingredients. The invention can be useful for the prevention or treatment of various diseases associated with the activity of P2X receptors, such as chronic inflammatory diseases, inflammatory pain, neuropathic pain, autoimmune diseases, or degenerative diseases.

  公开号：

  KR101732732B1

文献信息

• 신규한 1-피페리디닐 이미다졸 기반 P2X7 수용체 길항제 및 이를 포함하는 암 세포 이동 및 침윤 억제용 조성물
  申请人：Gwangju Institute of Science and Technology 광주과학기술원(319980993815) BRN ▼410-82-07550

  公开号：KR20170085170A

  公开（公告）日：2017-07-24

  본 발명은 암 전이억제제로서 신규한 P2X7R 길항제 및 이들의 기능적 활성에 관한 것이다. 본 발명의 신규 화합물은 IL-1β 분비에 대해 강력한 억제효과 및 암세포의 침윤 및 이동을 억제시키는 효과를 나타내었다. 특히, 본 발명의 화합물 중 이미다졸-기반 유도체인 화합물 12g, 13k, 및 17d는 인 비트로 및 인 비보에서 강력한 길항활성을 나타내어, 새로운 암 전이억제 치료제로서의 개발을 기대할 수 있다.

  本发明涉及一种新的P2X7R拮抗剂作为抗癌转移药物以及它们的功能活性。本发明的新化合物显示出对IL-1β分泌具有强大的抑制作用，以及对癌细胞的浸润和迁移具有抑制作用。特别是，本发明的化合物中，咪唑基导向的化合物12g、13k和17d表现出在体外和体内中强大的拮抗活性，因此有望作为新的抗癌转移抑制剂进行开发。
• 신규한 우라실 유도체 및 이의 용도
  申请人：Gwangju Institute of Science and Technology 광주과학기술원(319980993815) BRN ▼410-82-07550

  公开号：KR101732732B1

  公开（公告）日：2017-05-08

  본 발명은 다양한 신규 우리실(uracil) 유도체 화합물 및 이들을 유효성분으로 포함하는 P2X 수용체 활성 억제용 조성물에 관한 것이다. 본 발명은 P2X 수용체의 활성과 관련된 다양한 질환, 즉 만성 염증성 질환, 염증성 통증, 신경병성 통증, 자가면역 질환 또는 퇴행성 질환의 예방 또는 치료에 유용하게 이용될 수 있다.

  This invention relates to various novel uracil derivatives and compositions for inhibiting P2X receptor activity, which include them as active ingredients. The invention can be useful for the prevention or treatment of various diseases associated with the activity of P2X receptors, such as chronic inflammatory diseases, inflammatory pain, neuropathic pain, autoimmune diseases, or degenerative diseases.
• Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion
  作者：Jin-Hee Park、Darren R. Williams、Ji-Hyung Lee、So-Deok Lee、Je-Heon Lee、Hyojin Ko、Ga-Eun Lee、Sujin Kim、Jeong-Min Lee、Aliaa Abdelrahman、Christa E. Müller、Da-Woon Jung、Yong-Chul Kim

  DOI：10.1021/acs.jmedchem.5b01690

  日期：2016.8.25

  The P2X7 receptor (P2X7R) has been reported as a key mediator in inflammatory processes and cancer invasion/metastasis. In this study, we report the discovery of novel P2X7R antagonists and their functional activities as potential antimetastatic agents. Modifications of the hydantoin core-skeleton and the side chain substituents of the P2X7R antagonist 7 were performed. The structure activity relationships (SAR) and optimization demonstrated the importance of the sulfonyl group at the R-1 position and the substituted position and overall size of R-2 for P2X7R antagonism. The optimized novel analogues displayed potent P2X7 receptor antagonism (IC50 = 0.11-112 nM) along with significant suppressive effects on IL-1 beta release (IC50 = 0.32-210 nM). Moreover, representative antagonists (12g, 13k, and 17d) with imidazole and uracil core skeletons significantly inhibited the invasion of MDA-MB-231 triple negative breast cancer cells and cancer cell migration in a zebrafish xenograft model, suggesting the potential therapeutic application of these novel P2X7 antagonists to block metastatic cancer.
• Structure–activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists
  作者：Jin-Hee Park、Ga-Eun Lee、So-Deok Lee、Hyojin Ko、Yong-Chul Kim

  DOI：10.1016/j.ejmech.2015.10.036

  日期：2015.12

  As an optimization strategy, the flexible structure of KN-62, a known P2X(7) receptor antagonist, was converted into conformationally constrained derivatives using pyrimidine-2,4-dione as the core skeleton. Various modifications at the 4-position of the piperazine moiety of the new lead compound were performed to improve P2X(7) receptor antagonistic activities, which were evaluated in HEK293 cells stably expressing the human P2X(7) receptor (EtBr uptake assay) and in THP-1 cells (IL-1 beta ELISA assay). According to the results, polycycloalkyl acyl or di-halogenated benzoyl substituents were Much more favorable than the original phenyl group of KN-62. Among these compounds, the trifluoromethyl-chloro benzoyl derivative 18m and adamantyl carbonyl derivatives 19g-19i and 19k showed potent antagonistic effects, with IC50 values ranging from 10 to 30 nM. In addition, the in vitro adsorption, distribution, metabolism, excretion, and toxicity (ADMET) profile of 18m was determined to be in acceptable ranges in terms of metabolic stability and cytotoxicity. These results suggest that pyrimidine-2,4-dione derivatives may be promising novel P2X(7) receptor antagonists for the development of anti-inflammatory drugs. (C) 2015 Elsevier Masson SAS. All rights reserved.